BTIG Research Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price

Glaukos (NYSE:GKOS) had its target price raised by BTIG Research from $123.00 to $131.00 in a report published on Wednesday morning, Marketbeat Ratings reports. BTIG Research currently has a buy rating on the medical instruments supplier’s stock.

Other research analysts also recently issued research reports about the stock. Truist Financial boosted their target price on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. UBS Group upped their price objective on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Citigroup raised their target price on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $125.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. Finally, Stifel Nicolaus increased their price target on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $132.54.

Glaukos Stock Up 4.5%

Shares of Glaukos stock opened at $124.04 on Wednesday. The stock’s 50-day moving average is $112.34 and its 200 day moving average is $96.59. Glaukos has a one year low of $73.16 and a one year high of $161.78. The firm has a market cap of $7.12 billion, a price-to-earnings ratio of -80.55 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.28) earnings per share. Equities research analysts anticipate that Glaukos will post -1.08 EPS for the current year.

Insider Buying and Selling at Glaukos

In related news, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the transaction, the chief operating officer owned 92,366 shares of the company’s stock, valued at $8,312,940. The trade was a 17.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the sale, the director directly owned 34,905 shares of the company’s stock, valued at $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 329,655 shares of company stock worth $37,752,234. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Glaukos

Several institutional investors have recently made changes to their positions in the company. Riverbridge Partners LLC lifted its position in shares of Glaukos by 41.0% during the 3rd quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after buying an additional 165,673 shares during the last quarter. Holocene Advisors LP raised its stake in Glaukos by 40.1% in the 2nd quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock valued at $108,030,000 after acquiring an additional 299,118 shares during the period. Baird Financial Group Inc. lifted its holdings in Glaukos by 17.7% during the second quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier’s stock valued at $6,546,000 after purchasing an additional 9,545 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in Glaukos by 4.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier’s stock worth $2,056,000 after purchasing an additional 800 shares during the period. Finally, Divisadero Street Capital Management LP purchased a new position in shares of Glaukos in the second quarter worth about $10,514,000. Institutional investors own 99.04% of the company’s stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: FDA approved a labeling update that allows re‑administration of the iDose TR implant, expanding the product’s use and potential lifetime revenue per patient; this is the primary catalyst lifting the stock. Read More.
• Positive Sentiment: Analysts maintain a constructive view: a consensus rating of “Moderate Buy” was published, reinforcing institutional confidence and supporting demand for the shares. Read More.
• Positive Sentiment: BTIG raised its price target from $123 to $131 and kept a “Buy” rating, implying further upside vs. recent levels and likely contributing to short‑term buying. Read More.
• Negative Sentiment: Two insiders disclosed sales: Joseph Gilliam sold 10,498 shares and Marc Stapley sold 15,000 shares. While insider selling can be routine, some investors view it as a mild negative signal on near‑term insider conviction. Read More.
• Negative Sentiment: Marc Stapley’s 15,000‑share sale was separately reported; investors may monitor whether further insider activity follows. Read More.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.